Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) Shares Outstanding (Weighted Average) (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $55.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 0.81% to $55.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55.7 million through Dec 2025, up 0.81% year-over-year, with the annual reading at $55.7 million for FY2025, 0.81% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $55.7 million in Q4 2025 for Connect Biopharma Holdings, roughly flat from $55.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $55.7 million in Q4 2025 to a low of $55.1 million in Q4 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $55.3 million across 3 years, with a median of $55.2 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 0.27% in 2024 and later rose 0.81% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $55.1 million in 2023, then increased by 0.27% to $55.2 million in 2024, then grew by 0.81% to $55.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CNTB at $55.7 million in Q4 2025, $55.5 million in Q3 2025, and $55.4 million in Q2 2025.